TEM Tempus AI, Inc.
Company Analysis
Latest News
🔴 Tempus AI is trading 4.3% down today amid broader AI-stock pressure and rate concerns
Tempus AI is trading at $68.11, down 4.25% at 9:50 a.m. Eastern on October 16, 2026, amid broader pressure on AI-related stocks; no clear company-specific...
🟢 Tempus AI is trading 4.7% up with no clear company-specific catalyst
Tempus AI is trading at $71.51, up +4.67%, with no clearly reported company-specific catalyst for the October 15 gain. - The highlighted Moderna/Merck...
🔴 Tempus AI is trading 4.5% down in pre-market amid broad technology and market pressure
Tempus AI is trading at $65.24, down 4.50% in pre-market amid broad technology and market pressure. - No new company-specific catalyst surfaced; its latest...
🔴 Tempus AI is trading 4.04% down — catalyst remains unclear
Tempus AI is trading 4.04% lower at $68.06, with the October 12 decline’s cause unclear. - No clear company-specific announcement or other catalyst surfaced in...
🟢 Tempus AI is trading 5% up with no clear catalyst identified
Tempus AI is trading 4.76% higher at $72.58 on October 9, 2026, with no specific intraday catalyst established by available evidence. - Recent coverage points...
🔴 Tempus AI is trading 4.9% down with no clear company-specific catalyst
Tempus AI is trading 4.9% lower at $66.92; no clear company-specific announcement or catalyst explaining the October 8 decline surfaced in available...
Tempus Expands Moderna-Merck Collaboration for Potential Cancer Therapy Launch
Tempus AI has expanded its multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157),...
🔴 Tempus AI is trading 10% down
Tempus AI is trading at $75.17, down -10.03%, with no clear company-specific catalyst for the October 6 decline confirmed in available reporting. - Broader...
🔴 Tempus AI is trading 4.74% down
Tempus AI is trading at $79.59, down 4.74%, with no clear company-specific catalyst confirmed for the October 6 decline. - FDA clearance for its ECG-MR...
🟢 Tempus AI is trading 4.3% up today — no specific catalyst confirmed
Tempus AI is trading up 4.34% at $87.18; no specific reason is confirmed. - In the prior session, shares rose 9.03% to close at $83.55. - An October 6 report...
🟢 Tempus AI is trading 4.35% up
Tempus AI is trading 4.35% up at $79.96 on October 5; no company-specific announcement dated October 5 was found to explain the move. - The latest listed...
Tempus AI Updates Personalis Merger Filing, Details $48.42 Price Floor
Tempus AI filed an amended Form S-4/A with the SEC on October 2, 2026, providing updated details on its pending acquisition of Personalis, Inc. Under the...
🟢 Tempus AI is trading 4.45% up today as weak payrolls ease rate-hike expectations
Tempus AI is trading at $79.91, up 4.45%, alongside a broader risk-on rally after September payrolls rose by just 29,000 and rate-hike expectations eased. -...
🔴 Tempus AI is trading 4% down today as Treasury yields weigh on markets
Tempus AI is trading 4.02% lower at $78.61 as rising Treasury yields weigh on markets, though no company-specific announcement clearly explains the decline. -...
🟢 Tempus AI is trading 4.2% up — catalyst remains unclear
Tempus AI is trading 4.2% higher at $86.05, with no confirmed catalyst for the move. - No new company announcement on September 30 clearly explains the rise;...
Tempus AI Secures FDA Clearance for Mitral Regurgitation Screening Tool
Tempus AI received U.S. Food and Drug Administration (FDA) clearance for ECG-MR AI, an algorithm that analyzes electrocardiograms (ECGs) to identify patients...
🟢 Tempus AI is trading 4.6% up today despite broader U.S. market declines
Tempus AI is trading higher despite broader U.S. markets moving lower on September 24, 2026; no company-specific catalyst was identified. - Trading at $80.09...
Goldman Sachs Upgrades Tempus AI to 'Hold' Amid Mixed Analyst Sentiment
The Goldman Sachs Group upgraded Tempus AI (TEM) to "Hold" from "Neutral." Overall analyst sentiment for the precision medicine company remains mixed. The...
Tempus AI's Growth Trajectory and AI Expansion Highlighted in Positive Analyst Review
Seeking Alpha reiterated a buy rating for Tempus AI on September 22, 2026, citing a 60% rally since its last analysis. The report highlighted robust growth in...
Tempus AI Secures $42M Recursion Deal Extension, Goldman Sachs Initiates Neutral
Tempus AI extended its data license agreement with Recursion Pharmaceuticals through November 2029. The amended contract guarantees $42 million in committed...